Transcripts for a new form of Sox5, called L-Sox5, and Sox6 are coexpressed with Sox9 in all chondrogenic sites of mouse embryos. A coiled-coil domain located in the N-terminal part of L-Sox5, and absent in Sox5, showed >90% identity with a similar domain in Sox6 and mediated homodimerization and heterodimerization with Sox6. Dimerization of L-Sox5/Sox6 greatly increased efficiency of binding of the two Sox proteins to DNA containing adjacent HMG sites. L-Sox5, Sox6 and Sox9 cooperatively activated expression of the chondrocyte differentiation marker Col2a1 in 10T1/2 and MC615 cells. A 48 bp chondrocyte-specific enhancer in this gene, which contains several HMG-like sites that are necessary for enhancer activity, bound the three Sox proteins and was cooperatively activated by the three Sox proteins in non-chondrogenic cells. Our data suggest that L-Sox5/Sox6 and Sox9, which belong to two different classes of Sox transcription factors, cooperate with each other in expression of Col2a1 and possibly other genes of the chondrocytic program.
Cartilage formation is a complex and essential process in vertebrates. Cartilages are obligatory templates for the formation of endochondral bones during development and also constitute permanent skeletal structures in the respiratory tract, in articular joints and other organs. Chondrocytes differentiate following condensation of mesenchymal cells in different locations of the embryo, including the frontonasal mass, branchial arches, sclerotomes and limb buds. Typically, chondrocytes express a set of genes encoding cartilage-specific extracellular matrix components such as collagen II (encoded by the Col2a1 gene), collagens IX and XI, and aggrecan. In growth plates, chondrocytes undergo further differentiation and hypertrophy, producing a matrix in which type X collagen is abundant and calcification occurs. Apoptosis follows and cartilage is replaced by bone. Our understanding of chondrogenesis at the molecular level is still limited. Several cytokines, including bone morphogenetic proteins, Indian Hedgehog, parathyroid hormone-related peptide and fibroblast growth factors, are involved in either skeletal patterning or discrete steps of the chondrogenic pathway, and several transcription factors, such as Hox and Pax family members, are involved in patterning of skeletal primordia (Cancedda et al., 1995; Erlebacher et al., 1995; Hall and Miyake, 1995). However, less is known about the transcription factors that control the determinative switch for chondrocyte differentiation and the activation of marker genes at each step of the chondrogenic cascade.
Our laboratory has used genes for specific cartilage matrix components to identify transcription factors that control gene expression in chondrocytes. We have shown that a multimerized 48 bp sequence in the first intron of Col2a1 is sufficient to confer chondrocyte-specific expression both in transgenic mice and in transient transfection of cultured cells (Lefebvre et al., 1996). SOX9 binds to the enhancer and activates Col2a1 constructs in transient transfections of non-chondrocytic cells (Lefebvre et al., 1997) and in transgenic mice (Bell et al., 1997). SOX9 also activates the Col2a1 gene when ectopically expressed in some non-cartilaginous sites in transgenic mice (Bell et al., 1997). Moreover, Sox9 is expressed along with Col2a1 during chondrogenesis in mouse embryos (Wright et al., 1995; Ng et al., 1997; Zhao et al., 1997). Therefore, direct activation of COL2A1 is believed to be an important function of SOX9 in chondrogenesis (Lefebvre and de Crombrugghe, 1998).
Several lines of evidence suggest that other transcription factors in addition to SOX9 may be needed to specify the high-level expression of COL2A1 in chondrocytes. Sox9 is expressed in cells that do not express Col2a1, such as those in genital ridges and specific areas of the embryonic heart (Ng et al., 1997; Zhao et al., 1997). Sox9 is highly expressed in the Sertoli cells of the testis and is involved in male gonad differentiation (Kent et al., 1996; Morais da Silva et al., 1996). The target genes of Sox9 in these cells and in chondrocytes are not clearly defined, but the phenotypes of these two cell types are so different that it is likely that Sox9 contributes to their differentiation by controlling expression of different genes. Different functions of Sox9 in these cells must be specified by differential expression of other factors. Ectopic expression of SOX9 in transfected cells, in which Col2a1 was silent, did not result in Col2a1 activation (V.Lefebvre and B.de Crombrugghe, unpublished data), and ectopic expression of SOX9 in transgenic mice led to activation of Col2a1 only in a subset of tissues within the domain of ectopic expression of SOX9 (Bell et al., 1997). We therefore hypothesized that other factors either activate or derepress SOX9 or cooperate with SOX9 in COL2A1-expressing cells.
We recently reported that the 48 bp enhancer of Col2a1 formed a large and abundant complex with nuclear proteins from chondrocytes but not from other cells (Zhou et al., 1998). These proteins were designated CSEPs, for chondrocyte-specific enhancer-binding proteins. They included Sox9 and unidentified protein(s). CSEPs appeared to contact the 48 bp DNA at several sites homologous to a consensus for HMG-domain proteins. Mutagenesis demonstrated a good correlation between binding of CSEPs to DNA and enhancer activity in chondrocytes, both in transient transfection experiments and in transgenic mice. In addition, we showed that two chondrocyte-specific enhancer elements located in the Col11a2 promoter contained HMG-like sites that were essential for enhancer activity and formation of an enhancer–CSEP-like complex (Bridgewater et al., 1998). These results suggested that other HMG-domain proteins cooperate with Sox9 to generate Col2a1 and Col11a2 enhancer activity and presumably gene expression in chondrocytes.
We show here that in addition to Sox9, CSEPs are composed of a new long form of Sox5 (L-Sox5), and of Sox6, which both are members of a Sox subclass different from that of Sox9. L-Sox5 and Sox6 harbor a coiled-coil domain that mediates protein dimerization and efficient binding to adjacent HMG DNA sites. The three Sox genes are coexpressed in chondrogenesis and cooperate in Col2a1 activation. Our data strongly suggest that L-Sox5, Sox6 and Sox9 together contribute to control Col2a1, and perhaps other important genes of the chondrocyte phenotype.
A long form of Sox5 (L-Sox5), Sox6 and Sox9 form complexes with the 48-bp Col2a1 enhancer
The CSEP proteins that form a chondrocyte-specific complex with the 48 bp Col2a1 enhancer were previously shown to include a protein or proteins with an apparent Mr of 75–95 kDa (Zhou et al., 1998). These proteins exhibited DNA-binding properties of HMG-domain proteins, including binding to several HMG-like sites in the Col2a1 48 bp enhancer, binding to a probe containing a consensus binding site for HMG-domain proteins (1HMG probe), binding to the minor groove of DNA and binding to DNA in the presence of poly(dG–dC) but not poly(dI–dC) (Zhou et al., 1998). We also obtained evidence that CSEP bound with high affinity to a tandem dimer of the 1HMG probe (2HMG probe) both in EMSA and in Southwestern blots (data not shown).
On the basis of these results, the 2HMG probe was chosen to clone cDNAs for CSEPs by the Southwestern screening approach. cDNA expression libraries were made from primary chondrocytes of newborn mouse ribs. Several clones that showed stronger binding to the 2HMG probe in the presence of poly(dG–dC) than poly(dI–dC) encoded sequences of Sox5 or Sox6. Interestingly, whereas the previously reported transcript for Sox5 had a length of 2 kb and encoded a 43 kDa protein (Denny et al., 1992), the Sox5 cDNA that was reconstituted from overlapping clones was 3.9 kb long and encoded a 75 kDa protein corresponding to Sox5 with an additional N-terminal sequence (data submitted to DDBJ/EMBL/GenBank; see later, in Figure 4). This long form of Sox5 was designated L-Sox5. Sox6 cDNA clones encoded Sox6 isoforms identical or very similar to those described for testis (data submitted to DDBJ/EMBL/GenBank; see later, in Figure 4).
Antibodies were generated against the C-termini of Sox5, Sox6 and Sox9, and affinity purified. In Western blotting, each antibody species specifically recognized its Sox protein target in extracts of fibroblasts transfected with Sox expression plasmids (Figure 1A). In EMSA, each antibody preparation specifically supershifted complexes formed between DNA and its target (Figure 1B). In Western blots of RCS cell extracts, the antibodies strongly reacted with proteins at the level of L-Sox5, Sox6 and Sox9 (Figure 1C), indicating that each of these Sox proteins was indeed made by these cells. The same reactions were seen with extracts of primary chondrocytes and chondrocytic MC615 cells (data not shown), but not with extracts of BALB/3T3 (Figure 1C) or 10T1/2 fibroblasts (see control lanes in Figure 1B). Note that Sox5 antibodies showed no reaction in chondrocyte samples at the level of the 43-kDa short form of Sox5. In extracts of adult mouse testis, Sox5 antibodies recognized Sox5 but not L-Sox5 (Denny et al., 1992). It appeared, therefore, that only L-Sox5 is made in chondrocytes, not Sox5, whereas only Sox5 is made in the testis. These protein data are consistent with RNA data, which show that chondrocytes express only the transcript for L-Sox5 and testis only the transcript for short Sox5 (see Figure 2A). In EMSA, L-Sox5 and Sox6 made in transfected fibroblasts formed complexes with the 48 bp Col2a1 enhancer probe that migrated at the level of the CSEP–DNA complex (Figure 1D). Sox5 did not bind to the 48 bp element. As shown previously (Zhou et al., 1998), SOX9 formed two complexes with the enhancer, a major one migrating faster than the CSEP–DNA complex and a minor one migrating at the level of the CSEP–DNA complex (Figure 1D). Sox5, Sox6 and Sox9 antibodies were each able to partially supershift the CSEP–48-bp-Col2a1 enhancer complex formed with RCS cell nuclear extracts (Figure 1E), indicating that each of these Sox proteins contributed to complex formation. A virtually complete supershift of the CSEP–DNA complex was obtained by incubating EMSA reactions with both Sox5 and Sox6 antibodies. No further supershift was visible when the three Sox protein antibodies were included in the reactions. The same results were obtained with primary chondrocyte extracts (data not shown). L-Sox5 and Sox6 therefore appeared to be predominant CSEP components.
Altogether these results indicated that three different Sox proteins, L-Sox5, Sox6 and Sox9, were present in chondrocytes and bound to the 48 bp Col2a1 element. L-Sox5 is a long product of the Sox5 gene that has not been identified previously.
L-Sox5, Sox6 and Sox9 contact several HMG-like sites in the 48 bp Col2a1 enhancer
The Col2a1 48 bp enhancer contains four HMG-like sites, each containing 5 or 6 bp of the 7 bp consensus HMG site (Figure 1F). Previously we showed that mutations that disrupted any one of sites 1–3 inhibited enhancer activity in chondrocytes in transgenic mice and partially inhibited binding of CSEP to the enhancer (mutants mA1, mA4 and mA6 in Figure 1F; Zhou et al., 1998). A mutation that disrupted site 4 also impaired binding of CSEP to the enhancer (mutant mA9 in Figure 1F). The effect of this mutation on enhancer activity has not been tested. A mutation that preserved all five HMG consensus nucleotides of site 2 did not affect the binding of CSEP (mA3 in Figure 1F) and only weakly inhibited enhancer activity in RCS cells (Zhou et al., 1998). A mutation that disrupted three sites completely inhibited binding of CSEP (mA8 in Figure 1F; Zhou et al., 1998). We also reported previously that subfragments of the 48 bp element containing either one of the four HMG-like sites alone were unable to bind CSEP or to compete with the 48 bp element for binding of CSEP (Lefebvre et al., 1996, 1997; Zhou et al., 1998; our data, not shown). These results indicated that the four sites of the 48 bp element cooperatively contributed to formation of the CSEP–enhancer complex.
As described previously (Lefebvre et al., 1997; Zhou et al., 1998), the faster-migrating SOX9–DNA complex was inhibited by mutation of site 3 but not by mutation of other sites (Figure 1F). In contrast, the slower-migrating SOX9–DNA complex was partially inhibited by mutations disrupting any of the four sites and was completely inhibited by mutation of several sites. These results are consistent with the notion that the faster-migrating complex was formed by binding of one molecule of SOX9 to site 3, whereas the slower-migrating complex was formed by cooperative binding of two or more SOX9 molecules to several sites on each DNA molecule.
Consistent with the results obtained with CSEP, binding of L-Sox5 or Sox6 to the 48 bp enhancer was partially inhibited by mutations that disrupted any one of the four HMG-like sites and completely inhibited by a mutation of several sites (Figure 1F). Mutation mA1 slightly but reproducibly inhibited binding of L-Sox5 and Sox6 to DNA. As seen with CSEP, L-Sox5 and Sox6 were unable to bind to DNA probes harboring only one of the Col2a1 HMG-like sites (data not shown). Taken together, these data indicated that L-Sox5 and Sox6 were able to contact cooperatively all four HMG-like sites of the Col2a1 48 bp enhancer.
In chondrocyte nuclear extracts, the faster-migrating complex of Sox9 with the 48 bp enhancer was not seen (Zhou et al., 1998; compare also extracts of RCS cells and extracts of SOX9-transfected 10T1/2 cells in Figure 1D), but antibody supershift experiments indicated that Sox9 was present in the slower migrating CSEP complex. This result strongly suggested that, in chondrocytes, Sox9 bound the 48 bp element not as a single molecule but in cooperativity with other Sox9, L-Sox5 or Sox6 molecules.
These data suggest a model whereby the four HMG-like sites of the 48 bp element and the three Sox proteins could participate in vivo in the formation of a large protein–enhancer complex that would activate expression of Col2a1 in chondrocytes. Consistent with this model in which mutation of any of the HMG-like sites would dismantle the protein–enhancer complex, we have observed that disruption of any of sites 1, 2 or 3 resulted in abolition of the activity of the enhancer in chondrocytes of transgenic mice (Zhou et al., 1998).
A search for other HMG consensus and HMG-like sites (with six nucleotides of the heptamer consensus) in 1 kb of Col2a1 promoter sequence and in a 468 bp element of the first intron (+1878/+2345), which acts as a strong chondrocyte-specific enhancer in transgenic mice (Zhou et al., 1995), revealed the presence of a few scattered sites, but no cluster of two or more binding sites for Sox9, L-Sox5 and Sox6 was found that resembled that of the 48 bp element (data not shown).
Long transcripts of the Sox6 and Sox5 genes are expressed in chondrocytes
In Northern blots of total RNA, the short transcripts of Sox6 (3.2 kb) and Sox5 (2 kb) were abundant in adult mouse testis, as expected (Figure 2A). These short transcripts were not expressed (or were expressed at a very low level in the case of Sox6) in chondrocytes or in any cell line or newborn mouse tissue examined (Figure 2A; data not shown). A 6.3 kb Sox5 transcript and a 7.7 kb Sox6 transcript were found in similar relative abundance in primary chondrocytes from ribs of newborn mice, as well as in RCS and early-passage MC615 cells (Figure 2A and B). These three chondrocyte cells were previously shown to be well differentiated, expressing Col2a1 at a high level in parallel with Sox9 (Lefebvre et al., 1997). When rib chondrocytes were allowed to dedifferentiate by two passages in monolayer culture, Sox5 and Sox6 expression sharply declined (Figure 2A), as did Col2a1 and Sox9 expression (Lefebvre et al., 1997). Transcripts of Sox5, Sox6 and Sox9 were found in some non-chondrocytic cell types, but in contrast to chondrocytes, none of the non-chondrocytic cells coexpressed the three Sox genes or expressed Col2a1 at high levels (Figure 2B; Lefebvre et al., 1997).
The long transcripts of Sox5 and Sox6 were present in the brain and some other non-cartilaginous tissues of newborn mice (Figure 2A and C). However, no non-cartilaginous tissue, besides brain and testis, was found to coexpress Sox9, Sox5 or and Sox6 (Figure 2A and C; Lefebvre et al., 1997). In testis, Sox9 expression is restricted to the somatic Sertoli cells (Kent et al., 1996; Morais da Silva et al., 1996); Sox5 is expressed as a short transcript in post-meiotic germ cells, mostly in round spermatids (Denny et al., 1992); and, since expression of Sox6 correlates with that of the protamine gene (Takamatsu et al., 1995), a marker of spermatid differentiation, it is possible that Sox6 is expressed in testis in the same cells and at the same time as Sox5. The three Sox proteins, therefore, do not appear to be expressed in the same cells in testis.
In conclusion, chondrocytes, and perhaps some brain cells, appear to express together long transcripts for Sox5 and Sox6 and transcripts for Sox9. Expression of these transcripts correlates with expression of Col2a1 in chondrocytes.
The long transcripts of Sox5 and Sox6 are coexpressed with Sox9 and Col2a1 during chondrogenesis in mouse embryos
Previous whole-mount in situ experiments showed that Sox6 was expressed in the developing nervous system of mouse embryos; expression was high in early-stage embryos, but disappeared by embryonic day 12.5 (Connor et al., 1995). To obtain information on Sox6 and Sox5 expression during chondrogenesis in mouse embryos, we performed a series of in situ experiments and compared the expression patterns of these two Sox genes with those of Sox9 and Col2a1. For Sox5, we chose a probe that recognized the long transcript of Sox5 but not the short transcript, since we were interested in sites of expression of the L-Sox5 protein only. For Sox6, two probes were tested that recognized either the long transcript only or both the long and short transcripts, since both transcripts appear to encode the same protein (Connor et al., 1995; Takamatsu et al., 1995); the two probes gave identical results (data not shown).
At about mid-stage embryogenesis (day 10.5 post-coitum), mesenchymal cells form prechondrocytic condensations at different sites in the embryo. The sclerotomal components of somites contain precursor cells for the axial skeleton, the head mesenchyme and first and second branchial arches will generate part of the craniofacial skeleton, and the lateral plate mesoderm and limb buds will give rise to the appendicular skeleton. Transcripts for L-Sox5 and Sox6 were found in all these sites together with Col2a1 and Sox9 RNAs (Figure 3A; Cheah et al., 1991; Wright et al., 1995; Ng et al., 1997; Zhao et al., 1997). The four RNAs also co-localized in some non-chondrogenic sites such as brain, neural tube, otic vesicles and notochord.
At day 12.5 of embryonic development, cartilage is actively forming in all future cartilaginous and endochondral skeletal structures, including cartilages of the nose and ear, the thyroid, cricoid and hyoid cartilages, Meckel's cartilage, cartilages of the base of the skull, ribs, vertebrae, forelimbs and hindlimbs (Figure 3B). High levels of transcripts for L-Sox5 and Sox6 were found in all these structures, together with Col2a1 and Sox9 RNAs. Expression of the four genes was also seen in some areas of the brain and spinal cord. Transcripts for Sox6 and L-Sox5, but not Sox9, were also visible in liver and a few other non-cartilaginous areas.
In the limbs of 15.5- and 17.5-day-old embryos (Figure 3C and D), expression of Col2a1 and of the three Sox genes was high in the cartilaginous templates of the radius and ulna, carpals, metacarpals and tibia, and in proliferating chondrocytes of growth plates. When chondrocytes became hypertrophic in growth plates, they activated expression of Col10a1 whereas RNAs, for all three Sox proteins disappeared rapidly and simultaneously and RNAs for Col2a1 disappeared more slowly. Only traces of Col2a1 and Sox RNAs were found after cartilage was replaced by bone and expression of Col1a1 was activated in osteoblasts.
In conclusion, RNAs for collagen II, L-Sox5, Sox6 and Sox9 were expressed simultaneously and at high levels from early stages of chondrogenesis in all cartilaginous sites in mouse embryos. Expression of the three Sox genes appeared to be inhibited just before Col2a1 expression in hypertrophic chondrocytes. These results are consistent with a role for all three Sox proteins in the activation of Col2a1 in chondrogenesis, and possibly also in the activation of other genes of the chondrogenic program.
Comparison of Sox5, L-Sox5 and Sox6 cDNAs and polypeptides
Connor et al. (1995) and Takamatsu et al. (1995) previously isolated Sox6 cDNA species from adult mouse testis cDNA libraries. The cDNAs reported by the two groups encoded slightly different proteins, called Sox6 and Sox-LZ, respectively. For convenience, we have renamed them Sox6A and Sox6B. The proteins differ in two segments, most likely encoded by alternatively spliced exons (Figure 4A). Segment 1 encodes a MAAAA amino acid sequence (S1A) in Sox6A and a SSAAA sequence (S1B) in Sox6B, with different A codons being used in S1A and S1B. Segment 2 encodes a 41-amino-acid sequence and is present only in Sox6A. When total cDNA from primary chondrocytes was used in the polymerase chain reaction (PCR) with primers flanking the region of the S1 and S2 segments, the amplified products had the size expected for Sox6A (478 bp) and Sox6B (355 bp) products (data not shown). Sequencing of the PCR products indicated that the longer product contained S1A and S2, and was identical to Sox6A. The shorter product contained S1A and lacked S2. It therefore corresponded to a new form of Sox6, which we have named Sox6C (Figure 4A). In DNA-binding and transactivation assays, the three forms of Sox6 displayed identical activities (data not shown). These PCR data and additional sequencing of Sox6 cDNA clones from chondrocyte cDNA libraries suggested that the short and long transcripts of Sox6 both encoded protein isoforms with minor differences. Sox6 cDNA clones obtained from chondrocyte libraries contained an additional 3′ untranslated sequence at the 3′ end of the previously reported cDNAs from testis (data submitted to DDBJ/EMBL/GenBank). The longest sequence was 1.5 kb and accounts in part for the difference between the long and short transcripts of Sox6.
The L-Sox5 cDNA that was reconstituted from overlapping clones contained a 2037 bp open reading frame that encodes a 679-amino-acid protein, with 287 amino acids N-terminal to, and in frame with, the 392-amino-acid Sox5 protein sequence (Denny et al., 1992) (Figure 4B–D). It contained 189 bp of 5′ untranslated sequence, with an in-frame stop codon 120 bp upstream of the first ATG (data not shown). The first three in-frame methionine codons are surrounded by sequences homologous to the Kozak consensus and are therefore putative translation initiation codons (data not shown). Sox5 (Denny et al., 1992) and L-Sox5 cDNAs share an uninterrupted 1571 bp sequence that includes the 1179 bp coding sequence of Sox5 (Figure 4B). Upstream and downstream of this region, the sequences available for the two cDNAs are totally different. Sox5 and L-Sox5 mature RNAs must therefore arise from differential splicing of primary transcripts in the 5′ and 3′ regions, and different promoter usage for the two RNAs cannot be excluded.
Previous comparison of the short Sox5 protein with Sox6A (Connor et al., 1995) indicated an overall high degree of identity (61%), with a maximum of 93% in the HMG DNA-binding domain (Figure 4C and D). By comparison, the HMG domains of Sox5 and Sox6 are only 54 and 53% identical to that of Sry, respectively, and 50% and 49% identical to that of Sox9. The N-terminal segment of L-Sox5 also has a high degree of sequence identity (72%) with the N-terminus of Sox6 (Figure 4C and D). Computer analysis of the protein sequences revealed two regions compatible with formation of coiled coils in L-Sox5 and Sox6 (Figure 4E) (Lupas, 1996). The more upstream coiled-coil domain is highly conserved between L-Sox5 and Sox6 (91% identity) and has a maximum probability score for coiled-coil formation of 1.0 in both proteins. It is particularly long, with 83 residues in L-Sox5 and 82 in Sox6, which implies that the coiled coil may complete almost 24 helical turns. It includes in its N-terminal part the leucine zipper previously identified in Sox6 (Connor et al., 1995; Takamatsu et al., 1995) and a glutamine-rich domain in its C-terminal part, referred to as a Q box (Kido et al., 1998) (Figure 4C). The more downstream coiled-coil domain is located in the sequence of L-Sox5 that is shared with Sox5. This domain is shorter, with 40 residues in Sox5 and 29 in Sox6. It has a maximum probability score of 1.0 in Sox5 but a low-probability score of 0.39 in Sox6. It is only moderately conserved between the two proteins (59% identity). No region of homology with Sox9 was found outside the HMG domain.
In conclusion, the striking identity of L-Sox5 and Sox6 in the first coiled-coil domain and in the HMG domain strongly suggests that each of these domains must serve one or several important functions. The presence of these domains in both proteins and the otherwise overall high degree of identity between the two proteins (67%) suggest that L-Sox5 and Sox6 may play similar roles in vivo.
Dimerization of L-Sox5 and Sox6 highly stabilizes binding to adjacent HMG sites on DNA
L-Sox5 and Sox6 bound to the 2HMG probe much more efficiently than to the 1HMG probe (Figure 5A). In contrast, SOX9 bound with similar efficiency to both probes. This observation, the presence of potential coiled coils in L-Sox5/Sox6 and the ability of Sox6 to homodimerize (Takamatsu et al., 1995) led to the hypothesis that dimerization of the proteins through their coiled coils might stabilize their binding to adjacent DNA-binding sites.
To test this hypothesis, various deletion forms of L-Sox5 were synthesized in vitro and treated with glutaraldehyde (Figure 5B), which has the ability to cross-link interacting polypeptides (Wong, 1991). After separation by SDS–PAGE (Figure 5C), polypeptides with the expected Mr were seen for each full-length and deleted protein species in samples treated with no glutaraldehyde. Upon treatment with glutaraldehyde, monomeric forms of Sox6 and L-Sox5 were less abundant, and polypeptide species appeared that had the apparent Mr of homodimers. Similarly, the 151/679 and 32/437 deletions formed cross-linked species with an Mr consistent with dimerization. In these deletions, the two coiled-coil domains were intact. Deletion 213/679, short Sox5 and deletion 32/221–304/437, all of which had the first coiled-coil domain partially or totally deleted, did not form specific cross-linked species, nor did SOX9. These results indicated that the first coiled-coil domain of L-Sox5, like that of Sox6 (Takamatsu et al., 1995), was involved in specific protein–protein interactions, most likely protein homodimerization. The second coiled-coil domain of L-Sox5, which is present in 213/679, short Sox5 and deletion 32/221–304/437, appeared to be unable to mediate protein dimerization by itself. It might, however, have a role in stabilizing protein dimerization through the first coiled-coil domain.
In EMSA (Figure 5D), deletion 151/679 bound DNA as efficiently as L-Sox5 (lanes 2 and 3), but deletion 213/679 did not (lane 4), nor did Sox5 (lane 5). The first coiled-coil domain of L-Sox5 (residues 158–240) was still intact in 151/679 but largely deleted in 213/679. It appeared therefore to be involved in the high affinity of L-Sox5 for the 2HMG probe. A protein truncated in the C-terminus (32/437) did not bind DNA (lane 6), an expected result given that the HMG domain was deleted.
When L-Sox5 was mixed with deletion 151/679, the respective complexes of the two proteins formed, but a third abundant complex also formed whose migration level indicated that it was likely to involve one molecule of each of the two proteins (lane 9). A similar intermediate complex also formed with Sox6 and 151/679 (lane 15). This result strongly suggested that L-Sox5 binds the 2HMG probe as a homodimer or heterodimer with Sox6. On the basis of its DNA-binding properties, a similar conclusion can be made for Sox6.
When L-Sox5 was mixed with deletion 213/679 (lane 10), only the complex of L-Sox5 homodimer with DNA formed, indicating that the coiled-coil domains of two molecules of L-Sox5 were needed for efficient binding to DNA. Also, when L-Sox5 was mixed with deletion 32/437 (lane 12), no heterodimers bound to the 2HMG probe, indicating that the two C-termini of L-Sox5 molecules (which included the HMG domain) were required to bind DNA.
Together, these results suggest a model (Figure 5E) in which binding of two molecules of L-Sox5 and Sox6 to adjacent HMG sites on DNA is highly stabilized by protein dimerization through the coiled-coil domains.
Cooperative activation of chondrocyte-specific Col2a1 constructs by L-Sox5, Sox6 and SOX9
The ability of L-Sox5, Sox6 and SOX9 to activate Col2a1 reporter constructs in non-chondrogenic cells was tested using constructs in which Col2a1 enhancer segments were placed in an intron downstream of the promoter, as is the case in the endogenous Col2a1 gene.
A construct with a 309 bp Col2a1 promoter (p309; Figure 6A) was previously shown to be inactive in chondrocytes of transgenic mice (Zhou et al., 1995). In transient transfection of 10T1/2 cells, this construct was slightly but reproducibly activated by L-Sox5/Sox6 but not by SOX9, and no cooperation occurred among the three Sox proteins (Figure 6B). A similar construct that included four tandem copies of the 48 bp enhancer [p309–(4x48); Figure 6A] was specifically expressed in chondrocytes both in transgenic mice (Lefebvre et al., 1996) and in transient transfection (data not shown). In non-chondrogenic cells, this construct was not activated by L-Sox5, Sox6 or a combination of L-Sox5 and Sox6 at a higher level than the p309 construct, and it was moderately activated by SOX9 (Figure 6C). Interestingly, when SOX9 was co-expressed with L-Sox5, Sox6, or both L-Sox5 and Sox6, a higher activation occurred than with any Sox protein alone, demonstrating cooperativity between SOX9 and L-Sox5/Sox6.
Similarly, a p309–(2x231) construct, which harbored two copies of a 231 bp Col2a1 chondrocyte-specific enhancer (Lefebvre et al., 1996), including the 48 bp element, was activated at a higher level by the three Sox factors together than by each Sox protein individually (Figure 6D). Deletion of a 10 bp sequence in the 231 bp enhancer, which corresponded to the 3′ end of the 48 bp element, abolished enhancer activity in chondrocytes (Lefebvre et al., 1997) and also transactivation by the three Sox factors (Figure 6D). In contrast to L-Sox5/Sox6, Sox4 and the short form of Sox5 did not activate the p309-(2×231) construct, nor did they cooperate with SOX9 to generate a high-level transactivation of the construct in fibroblasts (Figure 6E).
Together these results indicated that L-Sox5 and Sox6 significantly enhanced transactivation of Col2a1 constructs by SOX9. L-Sox5 and Sox6 appeared to function similarly, whereas the short form of Sox5 was inactive.
Cooperative activation of chondrocyte-specific genes by L-Sox5, Sox6 and SOX9
The ability of L-Sox5/Sox6 and SOX9 to activate the endogenous Col2a1 gene was tested in several cell types by Northern blot analysis after transient transfection with Sox expression plasmids. As described previously (Lefebvre et al., 1997), 10T1/2 cells spontaneously expressed Col2a1, but at a much lower level than did differentiated chondrocytes (Figure 7A). Following transfection of Sox plasmids, Sox RNAs and proteins accumulated in large amounts in the cells within 24 h, but rapidly disappeared during the next 48 h (Figure 7A). A significant increase in the Col2a1 mRNA level was observed 24 h after transfection of either SOX9 or L-Sox5/Sox6 plasmids (Figure 7A and B). Depending on the experiments, SOX9 was either as potent as, or more potent than, L-Sox5/Sox6. The increase in Col2a1 RNA was transient and no longer detectable after 48 h (Figure 7A), and was therefore concomitant with high levels of Sox proteins. The same results were observed whether L-Sox5 and Sox6 were tested alone or together, indicating that they had redundant activities (data not shown). No significant increase in Col2a1 expression was observed when the cells were transfected with an expression plasmid for Oct-1, a POU-domain transcription factor capable of binding to the 48 bp Col2a1 enhancer (data not shown). This result demonstrated the specificity of Sox protein activity. Interestingly, coexpression of SOX9 and L-Sox5/Sox6 resulted in a much higher activation of Col2a1 expression than when each Sox protein was expressed individually. Similar results were obtained with MC615 cells (Figure 7B), which were tested after repeated passages in culture when expression of chondrocyte markers was severely reduced or lost. Their low level of Col2a1 expression was slightly stimulated upon expression of SOX9 alone or L-Sox5/Sox6, but it was strongly stimulated by coexpression of the three Sox proteins. When the cell culture medium was supplemented with bone morphogenetic protein 2 (BMP-2), a cytokine known to promote chondrogenesis (Reddi, 1998), Col2a1 RNA level also increased. In this condition also, overexpression of the three Sox factors highly stimulated Col2a1 expression. When cells that did not spontaneously express Col2a1 were tested, such as skin primary fibroblasts from newborn mice, BALB/3T3 fibroblasts and COS cells, no induction of Col2a1 expression was detected following transfection of Sox protein expression plasmids (data not shown).
Activation by L-Sox5/Sox6 and SOX9 of other genes expressed in chondrocytes along with Col2a1 was also examined (Figure 7B). The aggrecan gene, which encodes the protein core of a large aggregating proteoglycan found in abundance in cartilage, was weakly expressed by dedifferentiated MC615 cells, but overexpression of the three Sox proteins led to a clear increase in its RNA level. RNA for Col9a2, which codes for the α2 chain of type IX collagen, was undetectable in MC615 cells and not induced by any of the three Sox protein expression plasmids. RNAs for aggrecan and Col9a2 were not detectable in 10T1/2 cells, even after transfection of the three Sox protein expression plasmids (data not shown).
RNA levels of genes that are expressed in chondrocytes but not in parallel with Col2a1 were examined in order to test the specificity of gene transactivation by the three Sox proteins. Col10a1, a characteristic marker of hypertrophic chondrocytes, was expressed at low levels in MC615-dedifferentiated cells, but its expression was not affected by transfection of Sox protein expression plasmids. The genes for matrix Gla protein (MGP) and osteopontin, two extracellular matrix proteins produced by chondrocytes and also some other cell types, were expressed in MC615 cells, but transfection of the three Sox factors did not significantly affect their RNA levels (Figure 7B).
In conclusion, L-Sox5/Sox6 and SOX9 were found to stimulate cooperatively expression of Col2a1 and also aggrecan, two major markers of chondrocytes. These data strongly suggest that the three sox proteins together control important aspects of the chondrocyte phenotype.
We have shown here that a new form of Sox5 (L-Sox5) and Sox6, which both are dimeric Sox proteins that preferentially bind to adjacent HMG sites rather than to isolated sites, are coexpressed with Sox9 during chondrogenesis, efficiently bind to several HMG-like sites in the 48 bp chondrocyte-specific Col2a1 enhancer, and cooperate with SOX9 in activating the chondrocyte marker gene Col2a1.
L-Sox5 differs from Sox5 by an additional 287 amino-acid sequence at the N-terminus. L-Sox5 and Sox6 show a striking degree of identity in the HMG DNA-binding domain located in the C-terminal part and in a coiled-coil domain located in the N-terminal part. This coiled-coil domain has been shown previously to mediate homodimerization of Sox6 (Takamatsu et al., 1995), and we have shown that L-Sox5 also dimerizes through this domain, either with itself or with Sox6. Sox12, Sox13 and Sox23 (Komatsu et al., 1996; Kido et al., 1998; Yamashita et al., 1998) also feature a similar coiled-coil domain and their HMG domain is much more similar to those of L-Sox5 and Sox6 than to those of Sry, Sox9 and other Sox family members. Based on these similarities, the five Sox proteins are classified as Sox subgroup D (Wright et al., 1993; Yamashita et al., 1998). We have presented strong evidence that dimerization of L-Sox5/Sox6 highly stabilizes binding to DNA at adjacent recognition sites. Indeed, L-Sox5 and Sox6 bound to an element harboring two HMG sites much more efficiently than to an element harboring a single site. Two molecules of Sox polypeptides were binding to one molecule of 2HMG probe, and both the HMG and coiled-coil domains of the two polypeptide molecules were required for efficient DNA binding. SOX9, which does not homodimerize, did not bind to the 2HMG probe more efficiently than to the 1HMG probe. The complementary roles of the coiled-coil and HMG domains of L-Sox5/Sox6 in DNA binding probably account for the high degree of conservation of both domains in D-Sox family members. It also implies that target genes for these Sox proteins must harbor pairs of HMG binding sites with a configuration compatible with binding of D-Sox protein dimers.
Transcripts for L-Sox5 and Sox6 were expressed along with Sox9 in all prechondrogenic areas and cartilages during mouse embryonic development. Expression of all three Sox genes was inhibited when chondrocytes became hypertrophic in growth-plate cartilages; in these cells expression of the chondrocyte marker gene Col2a1 is also downregulated. Sox9, Sox5 (transcript for L-Sox5) and Sox6 were also expressed in some non-cartilaginous sites, such as notochord, otic vesicles and some areas of the brain, but they were not coexpressed where Col2a1 was not expressed. In cell cultures, the three Sox genes were coexpressed only in primary chondrocytes and chondrocytic cell lines, both of which highly expressed Col2a1, and a sharp decrease in the three Sox RNA levels accompanied loss of Col2a1 expression during chondrocyte dedifferentiation. We have also shown that the three Sox proteins were present in chondrocytes.
Our data indicate that when SOX9 and L-Sox5/Sox6 were transfected individually in 10T1/2 and MC615 cells, they only produced a modest increase in expression of the endogenous Col2a1 gene. However, upon cotransfection, cooperativity occurred among the three Sox proteins, leading to expression levels of Col2a1 that were an order of magnitude or more higher than in control cells. Expression of aggrecan was also significantly increased in MC615 cells transfected with the three Sox protein expression plasmids. The two classes of Sox proteins, L-Sox5/Sox6 and Sox9, are therefore able to cooperate functionally with each other in the activation of both Col2a1 and aggrecan. These results, together with the strong correlation that exists between expression of Col2a1, aggrecan (Glumoff et al., 1994) and the three Sox genes during chondrogenesis in mouse embryos, support the notion that the three Sox proteins may also play a role in the activation of Col2a1, aggrecan and possibly other chondrocyte marker genes in vivo.
A 48 bp element in the first intron of Col2a1 was previously shown to be sufficient to direct expression of a reporter gene in cartilage of transgenic mice and to contain sites essential for the activity of longer Col2a1 enhancer segments in chondrocytes (Lefebvre et al., 1996; Bell et al., 1997; Zhou et al., 1998). This element is therefore likely to be involved in Col2a1 expression in chondrocytes. Sox9, L-Sox5 and Sox6 bound to the 48 bp enhancer at four HMG-like sites, three of which were demonstrated to be necessary for enhancer activity in chondrocytes (Lefebvre et al., 1996; Bell et al., 1997; Zhou et al., 1998), whereas the role of the fourth has not been tested. On their own, L-Sox5/Sox6 were weak activators of Col2a1 enhancer constructs. However, they efficiently cooperated with SOX9 in the activation of the enhancer, leading to a level of activation that was several-fold higher than when each Sox protein was transfected individually. The promoter–enhancer configuration in these constructs was similar to that of the endogenous Col2a1 gene, in which the chondrocyte-specific enhancer is located in the first intron downstream of the transcription start site. L-Sox5/Sox6 were able to contact all four HMG-like recognition sites of the 48 bp Col2a1 enhancer. They probably bound as dimers, as their complexes with the enhancer and with the 2HMG probe migrated at the same level. Even though the binding sites for L-Sox5/Sox6 in the 48 bp enhancer are different from the preferred binding sites of the short Sox5 (AACAAT and AACAAAG; Denny et al., 1992), our experiments indicate that L-Sox5/Sox6, as well as SOX9, efficiently bound to the enhancer. It is possible that the proximity of several HMG-like sites in the enhancer was favorable to cooperativity between the two types of Sox proteins in achieving transcriptional activation.
Together the three Sox factors enhanced Col2a1 and aggrecan expression in cells that expressed low levels of these genes, but they did not induce Col2a1 expression in cells in which the gene was silent, even though they activated Col2a1 constructs at high levels in transient transfection of these same cells. It is possible that additional factors or coactivators may be needed to open the chromatin of chondrocyte-specific genes that were silent in the cells that were tested or that these genes were inactivated by other epigenetic mechanisms. Bell et al. (1997) reported that Sox9 was capable of activating Col2a1 in some ectopic sites of transgenic mouse embryos. It is possible that the Col2a1 gene is not repressed in mouse embryos as it might be in tissue culture cells or that the ectopic sites in which Sox9 was able to activate Col2a1 contained factors that allowed Sox9 to activate Col2a1.
Denny et al. (1992) reported that Sox5 was unable to activate transcription from a minimal promoter linked to multimerized Sox5 binding sites. In our experiments, L-Sox5/Sox6 were able to activate Col2a1 constructs whereas Sox5 was not. The more efficient binding of L-Sox5/Sox6 to DNA, compared with that of Sox5, is sufficient to explain why L-Sox5/Sox6 transactivated whereas Sox5 did not. But it is also possible that the N-terminus of L-Sox5/Sox6 harbors one or more domains involved in transactivation. Takamatsu et al. (1995) reported that full-length Sox6 was unable to transactivate a reporter construct containing four copies of an HMG-binding site. Transactivation and DNA binding occurred upon deletion of the leucine zipper of the protein. In our experiments, L-Sox5/Sox6 bound to the Col2a1 enhancer and transactivated Col2a1 constructs as full-length proteins. Differences between the two studies may be due to differences in DNA targets. It may be that the sequence of the Col2a1 enhancer, which is a potential target of L-Sox5/Sox6, the distance between HMG-like sites and eventually the presence of binding sites for additional activators are essential for L-Sox5/Sox6 binding to DNA and transactivation function.
The function of L-Sox5/Sox6 in vivo is not known. The ability of L-Sox5/Sox6 to cooperate with SOX9 in Col2a1 activation and the strong correlation between expression of L-Sox5/Sox6 and chondrogenesis suggest that mutations in the SOX5 and SOX6 genes might result in cartilage malformation diseases of still unknown causes. However, because of a possible redundancy of these two highly similar factors, a mutation in only one of their genes might cause only mild or no skeletal abnormalities. Although L-Sox5 and Sox6 belong to the same family of DNA-binding proteins as Sox9, and present the same expression pattern as Sox9 in chondrogenesis, it is unlikely that they play the same role as Sox9 because they differ substantially from Sox9 in DNA-binding and transactivation properties. The severe phenotype of patients with campomelic dysplasia, in which mutations in SOX9 are heterozygous, also strongly suggests that no other protein with a function that overlaps that of SOX9 exists in chondrocytes. Our data strongly suggest that Sox9 and L-Sox5/Sox6 represent two different subclasses of Sox proteins that are coexpressed during chondrogenesis, where they have distinct, complementary roles in the activation of important chondrocyte phenotype markers such as Col2a1.
Materials and methods
cDNA libraries were made from primary chondrocytes of ribs of newborn mice. Total RNA was isolated from cells cultured for 2–3 days (Lefebvre et al., 1994). Poly(A)+ RNA was purified using the Poly(A) Quick mRNA isolation kit from Stratagene (La Jolla, CA). Synthesis of double-stranded cDNA and ligation of adaptors were performed using the Superscript Choice system from Gibco-BRL (Gaithersburg, MD). Priming was performed with a mixture of oligo-dT and random hexamers. One expression library was made in the λgt11 phage vector and another in the λTriplEx phagemid vector from Clontech (Paolo Alto, CA). λ DNA was packaged with Gigapack III Gold Packaging extract (Stratagene). Southwestern screening was performed according to the method of Vinson et al. (1988) and Singh et al. (1989), and Clontech's instructions, after denaturation of filters with guanidine hydrochloride. Filters were preincubated for 30 min in incubation buffer (20 mM HEPES pH 7.9, 10% glycerol, 0.1% Nonidet P-40, 0.5 mM EDTA, 1 mM PMSF, 2 μg/ml leupeptin, 2 μg/ml pepstatin and 0.5 mM DTT) and further incubated for 2 h in new buffer, supplemented with 50 fmol/ml of 32P-labeled 2HMG probe and 1 μg/ml poly(dG–dC) or poly(dI–dC). Filters were washed four times for 1 min in incubation buffer and autoradiographed. New segments of L-Sox5 and Sox6 cDNAs were sequenced on both strands. A fragment of Sox6 cDNA was amplified by PCR using primers encompassing two HincII restriction sites in the coding sequence and first-strand cDNA from mouse chondrocytes or adult testis. PCR products were electrophoresed in agarose gel, eluted and sequenced.
Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as described previously (Lefebvre et al., 1997) using a 1HMG or Col2a1 48 bp probe (Lefebvre et al., 1997), or a 2HMG probe. The latter probe consisted of two tandem repeats of the 1HMG probe with BamHI and BglII-cleaved sites at the 5′ and 3′ ends, respectively, and with the two repeats linked by the sequence GGATCT. Extracts from transfected fibroblasts were made in 100 mM potassium phosphate buffer, pH 7.2, containing 0.2% Triton X-100. Proteins were synthesized in vitro using the TNT T7 Quick Coupled Transcription/translation system (Promega, Madison, WI) and the expression plasmids described below.
Antibody preparation and Western blotting
Antisera were raised in rabbits (Genosys Biotechnologies, The Woodlands, TX) using keyhole limpet hemocyanin conjugated to a peptide homologous to the C-terminus of Sox9 (Bridgewater et al., 1998) or corresponding to a sequence in the C-terminus of either Sox5 (PDVDYGSDSENHIAG) or Sox6 (PKSDYSSENEAPEPV). Specific antibodies were purified as described previously (Bridgewater et al., 1998). Purified antibodies (∼0.1 mg/ml) were dialyzed against phosphate-buffered saline. Western blots were prepared as described previously (Lefebvre et al., 1997) with Sox protein antibodies diluted 1:1000.
Probes for Northern blotting and in situ hybridization
A NcoI–NruI 552 bp fragment of mouse L-Sox5 cDNA, located in the 5′ end of the coding sequence, specifically hybridized with the long transcript of Sox5. A NcoI 448 bp fragment of Sox5 cDNA, which included the HMG box, specifically hybridized with the short and long transcripts of Sox5. A BglII–HindIII 454 bp fragment of Sox6 cDNA, located 1.3 kb downstream of the stop codon, specifically hybridized with the long transcript of Sox6. An AccI–PstI 478 bp fragment of Sox6 cDNA, located in the 5′ end of the coding sequence, specifically hybridized with the short and long transcripts of Sox6. The aggrecan probe was a 650 bp fragment of the mouse cDNA, encoding the C-terminal half of the G2 domain and most of the KS adjacent domain (Walcz et al., 1994). Other probes were as described previously (Lefebvre et al., 1995, 1997).
Total RNA was isolated and analyzed in Northern blots as described previously (Lefebvre et al., 1997). To facilitate transfer of large RNA species to nylon membrane, agarose gels were treated with 50 mM NaOH for 15 min before blotting. RNA standards were from Gibco-BRL. Hybridization signals were quantified on autoradiograms using the Intelligent Quantifier software program from Bio Image (Ann Arbor, MI).
In situ hybridization
Preparation of mouse embryo sections and hybridization with sense and antisense RNA probes labeled with [α-35S]UTP were performed as described previously (Zhao et al., 1997). Autoradiograms with collagen and Sox RNA probes were developed after 1 and 6–7 days, respectively. Sense probes showed no detectable signal over background.
Full-length mouse L-Sox5 and Sox6 coding sequences and deletions 151/679 and 213/679 were amplified by PCR and cloned into the pcDNA–5′UT and pcDNA–5′UT-FLAG mammalian expression plasmids, as described previously for human SOX9 and mouse Sox5 and Sox4 (Lefebvre et al., 1997). The FLAG epitope did not affect DNA binding and transactivation properties of any Sox protein (data not shown). PCR products were verified by DNA sequencing. To obtain deletion 32/437, an NcoI fragment of L-Sox5 cDNA was blunted and cloned into blunt-ended BamHI and EcoRI sites of pcDNA–5′UT–FLAG; a translation termination codon was located in the XbaI site located downstream of the EcoRI site. Deletion 32/221–304/437 in L5 was obtained by cutting off a PstI fragment in deletion 32/437. Sox6B (previously called SoxLZ) cDNA was a gift from Tadayoshi Shiba and Shinya Yamashita (Takamatsu et al., 1995). Sox6A and Sox6C coding sequences were reconstituted by replacing the HincII fragment of Sox6B cDNA with Sox6A- and Sox6C-specific fragments, which were obtained by PCR.
Synthesis of protein in vitro and cross-linking
Protein was synthesized in vitro with [35S]methionine. For cross-linking, 2 μl of protein sample was preincubated for 30 min in 7 μl of DNA-binding buffer, with or without 5 fmol of 2HMG oligonucleotide, and incubated for 10 min with 1 μl of 0.1% glutaraldehyde. Polypeptide species were separated by SDS–PAGE in a polyacrylamide gradient (5–12%) gel and revealed by autoradiography.
All cell types were cultured as described previously (Lefebvre et al., 1997). Primary chondrocytes from ribs of newborn mice were used, unless otherwise indicated, after 2–3 days in culture, when they were essentially fully differentiated (Lefebvre et al., 1994). RCS cells were previously shown to display a highly stable phenotype of early-stage chondrocytes (Mukhopadhyay et al., 1995). MC615 cells were used after early passage when they exhibited a fairly differentiated chondrocytic phenotype (Mallein-Gerin et al., 1993) or after repeated passages when they had essentially lost their chondrocytic phenotype. Human recombinant bone morphogenetic protein-2 (Genetics Institute, Cambridge, MA) was added to the culture medium at a concentration of 150 ng/ml.
The p309 Col2a1–βgeo reporter construct has been described previously (Zhou et al., 1995). The βgeo gene encodes a fusion protein with E.coli β-galactosidase and neomycin-resistance activities. Constructs p309–(4x48), p309–(2x231) and p309–(2x221) were obtained by cloning wild-type and mutant enhancer fragments (Lefebvre et al., 1996) into p309 as described previously for other constructs (Zhou et al., 1995). Reporter constructs were cotransfected with Sox protein expression plasmids using lipofectamine (Gibco-BRL) (Lefebvre et al., 1997). A plasmid, pSV2βgal or pGL2 (Promega), was included in all transfections as an internal control for transfection efficiency. Reporter activities were determined after normalization for transfection efficiency. Reporter and control plasmids were transfected in a 3:1 ratio, and expression plasmids were included in various amounts, as indicated. Empty expression plasmid was added, whenever necessary, to transfect the same total amount of DNA in all samples. To assess expression of endogenous genes, cells were transfected using either lipofectamine or FuGENE 6 (Boehringer Mannheim, Indianapolis, IN) according to the manufacturer's instructions.
DDBJ/EMBL/GenBank accession numbers
The accession Nos are: L-Sox5, AJ010604; Sox6, AJ010605.
SOX refers to human proteins; Sox refers to mouse proteins. Genes are italicized.
This work was funded by NIH grants R01 AR42909 and P01 AR42919–02 to B.d.C. V.L. is the recipient of an Arthritis Investigator Award from the Arthritis Foundation. We thank James H.Kimura for RCS cells, Bjorn Olsen for MC615 cells, the Genetics Institute for BMP2, Tadayoshi Shiba and Shinya Yamashita for Sox-LZ cDNA, Kurt J.Doege for the mouse aggrecan probe, Gérard Karsenty for the MGP probe and William T.Butler for the osteopontin probe and ROS 17/2.8 cells. We are grateful to Sankar N.Maity for precious advice, Heidi Eberspaecher, Xin Zhou, Ni Lu and Laura C.Bridgewater for help in experimental work, and Shane Zhao for help in analysis of cDNA and protein sequences. DNA sequencing was performed by The University of Texas M.D. Anderson Cancer Center core sequencing facility, which is supported by NCI grant CA16672. We thank William H.Klein, Richard R.Behringer, Randy L.Johnson and Sankar N.Maity for critical reviewing of the manuscript.